Instil Bio, Inc.
$8.39
0%
2026-04-21 09:49:00
instilbio.com
NCM: TIL
Explore Instil Bio, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$56.9 M
Current Price
$8.39
52W High / Low
$42.79 / $5.67
Stock P/E
—
Book Value
$16.79
Dividend Yield
—
ROCE
-26.15%
ROE
-50.39%
Face Value
—
EPS
$-10.7
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
2.03
Debt / Equity
70.52
Current Ratio
39.53
Quick Ratio
39.53
Forward P/E
-0.55
Price / Sales
—
Enterprise Value
$60.25 M
EV / EBITDA
-1.15
EV / Revenue
—
Rating
Buy
Target Price
$29
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Zentalis Pharmaceuticals, Inc. | $4.03 | — | $301.33 M | — | -57.45% | -49.54% | $6.95 / $1.13 | $3.13 |
| 2. | ArriVent BioPharma, Inc. | $31.39 | — | $1.31 B | — | -57.79% | -58.88% | $30.72 / $16.1 | $7.24 |
| 3. | Adicet Bio, Inc. | $8.67 | — | $83.2 M | — | -71.49% | -67.55% | $17.44 / $6.01 | $14.82 |
| 4. | VivoSim Labs, Inc. | $1.54 | — | $4.02 M | — | -115.61% | -51.07% | $5.3 / $1.25 | $1.7 |
| 5. | Genelux Corporation | $2.65 | — | $125.01 M | — | -259.44% | -1.7% | $8.54 / $2.25 | $0.31 |
| 6. | Zenas BioPharma, Inc. | $20.9 | — | $1.28 B | — | -65.85% | -1.36% | $44.6 / $8.09 | $4.44 |
| 7. | Jasper Therapeutics, Inc. | $1.06 | — | $28.56 M | — | -371.51% | -2.3% | $7.19 / $0.62 | $0.15 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -9.56 M | -15.02 M | -12.9 M | -14.48 M | -11.47 M | — |
| Net Profit | -8.19 M | -13.59 M | -21.39 M | -28.2 M | -11.89 M | — |
| EPS in Rs | -1.21 | -2 | -3.15 | -4.16 | -1.75 | -3.54 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -51.96 M | -56.05 M | -87.16 M | -203.29 M |
| Net Profit | -71.37 M | -74.14 M | -156.09 M | -223.18 M |
| EPS in Rs | -10.52 | -10.93 | -23.01 | -32.91 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 203.52 M | 263.57 M | 325.63 M | 482.13 M |
| Total Liabilities | 89.66 M | 94.13 M | 99.8 M | 118.52 M |
| Equity | 113.87 M | 169.44 M | 225.83 M | 363.61 M |
| Current Assets | 191.43 M | 124.47 M | 160.76 M | 269.38 M |
| Current Liabilities | 4.84 M | 7.9 M | 10.56 M | 32.79 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -36.62 M | -55.7 M | -82.03 M | -180.16 M |
| Investing CF | 25.48 M | 53.97 M | 41.13 M | 114.54 M |
| Financing CF | 7.29 M | 1.75 M | 8.08 M | 71.89 M |
| Free CF | -46.62 M | -65.7 M | -102.69 M | -264.75 M |
| Capex | -10 M | -10 M | -20.66 M | -84.59 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 52.5% | 30.06% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-12-08 | 1:0.05 |